Articles tagged with Flu Vaccines
Research by the University of Rochester Medical Center found that flu vaccines are effective in protecting children from respiratory viruses, even during years with poor vaccine matches. Vaccination is crucial for preventing illnesses, as it can prevent up to 2,250 hospitalizations and 270,000 to 650,000 doctor visits.
A recent study published in Pediatrics found that flu vaccination rates for adolescents with asthma and other illnesses are still low, ranging from 8-15% over the study period. However, the researchers suggest that a universal influenza vaccination approach may increase coverage among this population.
A novel intranasal influenza vaccine has elicited immune responses more than 20 times higher than traditional vaccines, using only half the standard antigen dose. The vaccine's nanoemulsion-based adjuvant system triggers unparalleled mucosal and systemic immunity without pro-inflammatory materials or cytokines.
A new model predicts that vaccinating infants with PCV7 can prevent over 357,000 deaths during an influenza pandemic while saving $7 billion in costs. The research also shows routine pneumococcal vaccination can reduce flu-related deaths and costs in a typical season.
Two studies published in PLOS Medicine show that increasing flu vaccination rates can decrease the burden of influenza. A universal immunization program in Ontario led to reductions in flu-related deaths, hospitalizations, and emergency department visits compared to other provinces.
A study found that a higher dose of flu vaccine boosts the immune response in people aged 65 and older, increasing antibody levels by 30-80% compared to the standard dose. This could lead to better protection against the flu for those most at risk.
A CDC-funded study found that vaccinating new mothers and family members against influenza before a newborn leaves the hospital significantly boosts immunization rates. The 'cocooning effect' also protects unprotected children from the flu, which can be life-threatening to infants.
A Phase III study found that the high-dose influenza vaccine increased immune responses to all three influenza strains compared to the standard vaccine in adults 65 years old and older. The new vaccine also showed increased immune response in those with no measurable protective antibodies before vaccination.
MedImmune presents nine abstracts on respiratory syncytial virus (RSV) and influenza, providing insight into infectious disease prevention. The research focuses on RSV therapy, healthcare costs, and mechanisms of action for the monoclonal antibodies palivizumab and motavizumab.
Researchers have discovered a single vaccine that can protect chickens, cats, and humans against deadly bird flu pandemics. The vaccine uses a 'backbone' from the H9N2 virus to offer universal protection across multiple species.
The Elsevier journal Vaccine released a comprehensive supplement dedicated to influenza vaccines, supported by the International Federation of Pharmaceutical Manufacturers and Associations. Key findings include discussions on pandemic influenza vaccine challenges and the importance of robust global surveillance systems.
A new study has found that a single low-dose booster vaccine can generate an excellent response in people who have been vaccinated up to 7 years ago. This means that proactively immunizing the public with stockpiled pre-pandemic vaccines could be used as a potential vaccination strategy against pandemic influenza.
A recent study published in Archives of Pediatrics & Adolescent Medicine found that the flu vaccine was not associated with reduced hospitalizations or outpatient visits among children under 5. The mismatch between the strains of virus in the vaccine and circulating strains may have contributed to this outcome.
A hospital-based case-control study found that pneumococcal vaccination was associated with a 50% lower risk of heart attacks two years after vaccination. The study suggested that the pneumonia vaccine may protect against heart attacks by preventing pneumonia, which has been linked to triggering heart attacks.
Researchers at Duke University Medical Center found that a maternal diet rich in methyl donors increases the development and severity of asthma in mice. The study also identified specific genes modified by methylation as likely underlying causes of the increased disease severity.
Researchers have found that adding a new component to vaccines for influenza might enable broad protection against avian and seasonal influenza A viruses. Memory T cells from individuals infected with seasonal influenza A cross-react with H5N1, suggesting improved immunity.
A study conducted in Bangladesh found that vaccinating mothers during pregnancy with the flu shot can greatly reduce a newborn's risk of infection, with a 63% reduction in proven influenza illness among infants. The study also showed a 36% decrease in serious respiratory illnesses for both mothers and infants.
Researchers analyzed data from over 700 elderly patients and found no significant reduction in all-cause mortality among those vaccinated against flu. Despite initial reports of a large mortality benefit, the study controlled for various variables and concluded that any potential benefit was small and statistically non-significant.
Scientists at the University of Pittsburgh Center for Vaccine Research are testing vaccines designed to protect against the deadliest strain of avian flu, H5N1. The $3.6M grant will support animal studies using virus-like particles that could potentially offer enhanced protection against new strains.
Researchers at UTMB have tested a new universal vaccine effective against multiple influenza strains, with promising results in a Phase I clinical trial. The vaccine candidate, VaxInnate's M2e, could provide a safe and highly effective solution to prevent seasonal and pandemic influenza A.
A Group Health study found that flu vaccination had no protective effect against pneumonia in elderly patients. The largest case-control study of flu vaccine use in the elderly revealed a lack of correlation between vaccination and reduced risk of pneumonia.
Researchers analyzed 1173 cases of community-acquired pneumonia and found that flu vaccination was not associated with a reduced risk. The study suggests that the vaccine may not be effective in reducing influenza infection in elderly individuals at risk of pneumonia.
A recent study suggests that booster vaccination with a newer strain of H5N1 avian influenza can be more effective than simply vaccinating with the current vaccine. The study shows that priming with an earlier vaccine can enhance immune responses to single-dose vaccination schedules, making it a potential strategy for pandemic control.
Researchers found that men vaccinated in the morning showed strongest immune response to both hepatitis and influenza vaccines. The study's results have implications for vaccination timing, suggesting that adults could be vaccinated at specific times of day to increase their protection against flu.
Researchers at the University of Pennsylvania School of Medicine have developed a potential new way to vaccinate against avian flu by using synthetic DNA vaccines that induce broad immune responses against pandemic flu. This approach could allow for quick mobilization during an epidemic and has implications for non-avian types of flu.
Researchers traced flu samples from around the world to determine migration patterns, finding Asia is the breeding ground for new strains. The study's 'antigenic map' shows relationships between viruses and helps predict future outbreaks.
Researchers have developed a rapid way to produce human monoclonal antibodies against the flu, overcoming technical barriers that slowed their development. The new technique could potentially be used for diagnosis and treatment of other infectious diseases.
Researchers have developed a faster way to generate human monoclonal antibodies against influenza virus by tapping the immune system at peak powers. The method was tested on human volunteers and showed promising results, potentially finding broad application towards almost any infectious disease.
A new vaccine under development has shown promising results in mice, protecting against highly pathogenic bird flu and its variants for a year or longer. The vaccine uses an adenovirus vector technology, which can be produced quickly and stored for long periods, making it an attractive option for pandemic preparedness.
A study found that flu viruses originating in East and Southeast Asia spread globally, with strains emerging in Asia first, followed by Europe and North America. The research aims to improve flu vaccine design by focusing surveillance efforts on these regions.
Researchers analyzed 13,000 virus samples from 2002 to 2007 to understand migration patterns of seasonal flu. They found that East and Southeast Asia serves as a source for influenza A (H3N2) viruses globally, with new strains emerging in the region before spreading to other parts of the world.
Research found that annual flu vaccines reduced acute respiratory illness and exacerbations of COPD by 67% and 50%, respectively. Patients with severe COPD experienced a 75% reduction in respiratory problems.
A new HIV/AIDS vaccine is being tested in a phase 1 clinical trial at Beth Israel Deaconess Medical Center in Boston. The vaccine uses a replication-incompetent adenovirus vector encoding an HIV-1 envelope gene, aiming to overcome the problem of preexisting immunity to common vaccine vectors.
A new study confirms the close link between viral colds and ear infections in young children, identifying adenovirus, respiratory syncytial virus, and coronavirus as primary causes. Researchers recommend avoiding exposure to sick children, day care attendance, and using influenza vaccine to prevent respiratory viral infection.
Researchers from UT Knoxville have made a groundbreaking discovery about memory B cells, which are crucial for fighting off influenza infections. By analyzing where these cells reside after an infection, scientists can develop more effective vaccines that target specific strains and subtypes of the flu virus.
A new study published in Pediatrics found that 23% of children hospitalized with influenza had a previous hospitalization during the most recent flu-vaccine season. This suggests that providing in-hospital vaccinations to those at highest risk may aid in reducing rates of pediatric hospitalization for influenza.
Researchers at the University of Pittsburgh's Center for Vaccine Research have developed a vaccine against the deadliest strain of avian flu, H5N1. The vaccine produced a strong immune response in mice and protected them from death following infection with the virus.
Scientists have discovered a way to eliminate the negative effect of M2 protein on anti-flu vaccination, increasing efficacy while maintaining safety. This breakthrough could lead to more effective and strain-specific vaccines against seasonal flu.
Global health experts Laurie Garrett and David Fidler propose stockpiling highly specific influenza vaccines and antiviral medicines in Hong Kong to overcome the virus sharing impasse. The proposal aims to benefit developing countries by ensuring they have access to vaccine, reducing the risk of pandemic influenza.
A study found significant decreases in illness and death rates for 13 vaccine-preventable diseases in the US, including near 100% declines for some diseases like diphtheria, measles, and smallpox. High vaccine coverage levels have contributed to these achievements.
A study found that antiviral medications significantly reduced the risk of death from flu in hospitalized adults, even when given up to four days after symptom onset. The research supports the use of antivirals for treating hospitalized patients with influenza.
NIAID has awarded eight contracts to strengthen and expand its VTEUs, which will carry out more clinical trials in larger populations and safely test vaccines in specific vulnerable populations. The units will have inpatient beds for isolating volunteers, making it easier to conduct trials quickly.
A study found that nearly a quarter of cancer patients receiving radiation therapy are not getting vaccinated against flu and pneumonia, posing a significant risk to their health. Oncologists can play a key role in informing patients about recommended vaccines during regular interactions.
Researchers found that influenza vaccine is less effective in rural children of Gabon compared to semi-urban counterparts due to co-infections and poor nutrition. This study highlights the need for tailored approaches to pandemic influenza prevention in developing countries.
Researchers found that influenza vaccine was more effective in a semi-urban population than in a rural population of schoolchildren in Gabon, Africa. Infection with parasites and/or poor nutrition may compromise immune responses to the flu vaccine.
A new flu vaccine delivered through painless microneedles in patches applied to the skin could soon be an alternative to hypodermic needles, offering less discomfort and lower costs. The Emory University and Georgia Institute of Technology team aims to design patches that can increase immunity to influenza with smaller amounts of vaccine.
Researchers at Texas A&M University are developing an aloe vera-based nosespray vaccine that has shown promising results in animal trials. The vaccine uses a gel-like substance to cling to the inside of the nose, allowing it to stay longer and work more effectively than traditional liquid sprays.
Researchers from NIH identify sources of bias in previous studies, suggesting strategies to reduce severe influenza outcomes among the elderly. The authors emphasize the need for better flu vaccines and new approaches, including antiviral drugs and targeted vaccination for high-risk individuals.
The Lancet Infectious Diseases report highlights frailty selection bias and non-specific trial endpoints as reasons behind the exaggeration. Few trials have included elderly people, especially those aged at least 70 years, which accounts for three-quarters of all influenza-related deaths.
A new study published in Pediatrics found that annual flu shots significantly reduce outpatient visits and hospitalizations due to flu-related illness. Vaccinating half of U.S. children could prevent up to 650,000 doctor's office visits and 2,250 hospitalizations per year.
Researchers developed a novel antigen-sparing adjuvant strategy to improve immunogenicity of the bird flu vaccine. The new formulation showed significant cross-clade immunity against H5N1 viruses and induced high levels of neutralizing antibodies, increasing protection against pandemic.
A new study by the New York Academy of Medicine highlights the critical need to address vaccination coverage among hard-to-reach populations. The authors propose achievable strategies to increase immunization rates among these groups, including unconventional site distribution and patient reminders.
A national survey found gaps in vaccine financing for underinsured children, leading to concerns about access to life-saving vaccinations like pneumococcal conjugate and meningococcal conjugate vaccines. The study highlights the need for improved funding and distribution of new pediatric vaccines at the state level.
Researchers at The Wistar Institute discovered a mechanism where the gene-transcription machinery can be paused by the ubiquitin molecule until a triggering signal is received. This pause allows for quick activation of genes in response to stress or vital needs, such as stem-cell differentiation.
Two new studies emphasize the importance of delivering measles and influenza vaccines to HIV-infected individuals. Measles vaccine administered at age 9 months showed limited protection in HIV-infected children, highlighting the need for supplementary vaccinations to maintain immunity. In contrast, rates of influenza vaccination among ...
Scientists are testing a universal flu vaccine that targets all 'A' strains of the virus, offering broad and lifelong protection. The vaccine has shown promising results in laboratory animals and is now being administered to a small group of healthy people in Phase I clinical trials.
A study predicts that using Tamiflu prophylactically could reduce illness and death rates during an influenza pandemic by half, with a cost savings of $70,000 per 1,000 population. Prophylaxis with antivirals or vaccines is considered a crucial strategy in the early months of a pandemic.
Researchers detected anti-Fluzone antibodies in 40% of cord blood specimens, establishing B and T cell responses to antigens occur in utero following maternal vaccination. This finding has significant implications for understanding when immune responses to environmental exposures begin.
Research highlights the influence of private hospital care on Medicaid patients, flu vaccine shortages, and smoking bans on health outcomes. Smoking bans at home and work significantly improve health status among nonsmokers, while racial diversity in neighborhoods affects pregnant women's decision to smoke.
Current health policy based on voluntary vaccinations is not enough to control severe flu epidemics and pandemics unless vaccination programs offer incentives to individuals. Free vaccinations for entire families could actually increase the frequency of severe epidemics, according to UCLA researchers.